A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
Clinical trial NCT06840392 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06840392
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-20
- Primary completion
- 2027-06-03
- Enrollment
- 565
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.